Pharmacology of insulin

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 1, 2004, Pages 10-14

  Ahmad, Bushra ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Analogues; Aspart; Detemir; Glargine; Insulin; Lispro; Pharmacology

Indexed keywords

ALBUMIN; AMINO ACID; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; SOMATOMEDIN C;

CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INJECTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIFESTYLE; MORBIDITY; MORTALITY; NONHUMAN; PH MEASUREMENT; QUALITY OF LIFE; REVIEW; VASCULAR DISEASE;

EID: 1542270210     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040010201     Document Type: Review

References (56)

1. Heinemann L, Richter B. Clinical Pharmacology of human insulin. Diabetes Care Dec 1993;16(suppl 3):90-100.
2. Chawdhury SA, Dodson EJ, Dodson GG et al. The crystal structures of three non-pancreatic human insulins. Diabetologia 1983;25:460-4.
3. Brogden RN, Heel RC. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987;34(3):350-71.
4. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.
5. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmokinetics. Diabetes Care 1984;7:188-99.
6. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983;6:374-7.
7. Brange J, Ribel U, Hansen JF et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988;333:679-82.
8. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54.
9. Brems DN, Alter LA, Beckage MJ et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992;5:527-33.
10. Di Marchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. Preparation of an insulin with improved pharmokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor 1. Horm Res 1994;41(suppl 2):S93-S96.
11. Radziuk JM, Davis JC, Pye WS et al. Bioavailability and bioeffectiveness of subcutaneous human insulin and two of it's analogues- LysB28, ProB29-human insulin and AspB10, LysB28, ProB29-human insulin-assessed in a conscious pig model. Diabetes 1997;46:548-56.
12. Somwar R, Sweeny G, Ramlal T, Klip A. Stimulation of glucose and amino acid transport and activation of the insulin signalling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther 1998;20:125-40.
13. Slieker LJ, Brooke GS, Di Marchi RD et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin after affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 1997;40(suppl 2):S54-S61.
14. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49(6):999-1005.
15. Glazer NB, Zalani S, Anderson JH Jr, Baastyr EJ 3rd. Safety of insulin lispro: pooled data from clinical trials. Am J Health Syst Pharm 1999;56(6):542-7.
16. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
17. Davey P, Grainger D, Macmillan J, Rajan N, Aristides M, Gliksman M. Clinical outcomes with insulin ispro compared with human regular insulin: a meta-analysis. Clin Ther 1997;19(4):656-7.
18. Anderson JH Jr, Brunelle RL, Koivisto VA et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997;19:62-72.
19. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24(3):430-4.
20. Del Sindaco P, Ciofetta M, Lalli C et al. Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabetic Medicine 1998;15:592-600.
21. Lalli C, Ciofetta M, Del Sindaco P et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77.
22. Stades AM, Hoekstra JB, van den Tweel I, Erkelens DW, Holleman F Stability Study Group. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults: real-life design. Diabetes Care 2002;25(4):712-17.
23. Joseph SE, Korzon-Burakowska A, Woodworth JR et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998;21:2098-102.
24. Anderson JH Jr, Brunelle RL, Koivisto VA et al. Reduction in postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46:265-70.
25. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000;17(3):209-14.
26. Anderson JH Jr, Brunelle RL, Keohane et al. Mealtime treatment with insulin analog improves postprandial hyperglycaemia and hypoglycaemia in patients with non-insulin dependent diabetes mellitus. Arch Int Med 1997;157:1249-55.
27. Holcombe JH, Zalani S, Arora VK, Mast CJ. Lispro in Adolesecents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002;24(4):629-38.
28. Heller SR, Ameil SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diabetes Care 1992;22(10):1607-11.
29. Brunelle RL, Llewelyn J, Anderson JH, Gale EAM, Koivisto VA. Meta-analysis of the Effect of Insulin Lispro on Severe Hypoglycaemia in Patients with Type 1 Diabetes. Diabetes Care 1998;21:1726-31.
30. Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL. Effect of Continuous Subcutaneous Insulin Infusion With Lispro on Hepatic Responsiveness to Glucagon in Type 1 Diabetes. Diabetes Care 1998;21:1627-31.
31. Jacobs MA, Salobir B, Popp-Snijders C, Ader H, Heine RJ. Counterregulatory hormone responses and symptoms during hypoglycaemia by porcine, human regular insulin and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers. Diabet Med 1997;14(3):248-57.
32. Torlone E, Fanelli C, Rambotti AM et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 1994;37:713-20.
33. McCrimmon RJ, Frier BM. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue lispro human insulin. Diabet Med 1997;14:929-36.
34. Schernthaner G, Wein W, Sandholzer K et al. Post prandial insulin lispro. A therapeutic option for type 1 diabetic patients. Diabetes Care 1998;21:570-3.
35. Kotsanos JG, Vignati L, Huster W et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care J 1997;20(6):948-58.
36. Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin Lispro and regular insulin in pregnancy. QJM 2001;94(5):255-60.
37. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003;26(5):1390-4.
38. Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2002;26(4):1193-8.
39. Volund A, Brange J, Drejer K et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 1991;8:839-47.
40. Dall V. Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart. Arzneimittelforschung 1999;49(5):463-70.
41. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25(5):876-82.
42. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22(9):1501-06.
43. Kang S, Brange J, Burch A, Volund A, Owens DR. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9, GluB27; AspB10, AspB28) in healthy subjects. Diabetes Care 1991;14:1057-65.
44. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23(5):583-8.
45. Home PD, Lindholm A, Riis A. Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17(11):762-70.
46. Frier BM, Ewing FM, Lindholm A, Hylleberg B, Kanc K. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Rev 2000;16(4):262-8.
47. Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes. Diabet Med 2000;17(5):371-5.
48. Halberg IB, Jacobsen LV, Dahl UL. A study on self-mixing insulin aspart with NPH insulin in the syringe before injection. Diabetes 1999;48(suppl 1):A104 (Abstract).
49. Barnett AH. A review of basal insulins. Diabet Med 2003;20:873-85.
50. Perriello G, De Feo P, Torlone E et al. The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991;34:21-8.
51. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-8.
52. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edward MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-6.
53. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 Diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000;23(2):157-62.
54. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. J Clin Endocrinol Metab 2001;86(12):5838-47.
55. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long acting insulin analogue NN304. Diabet Med 1999;16(4):332-8.
56. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26(3):590-6.